TRK inhibitor in a patient with metastatic triple-negative breast cancer and <i>NTRK</i> fusions identified <i>via</i> cell-free DNA analysis
Arielle J. Medford(Harvard University), Aditya Bardia(Harvard University), Laura M. Spring(Massachusetts General Hospital), Bariş Boyraz(Harvard University), Tasos Gogakos, Phoebe Ryan(Harvard University), Leif W. Ellisen(Harvard University), Charles S. Dai(Cleveland Clinic Lerner College of Medicine), Lesli A. Kiedrowski(Guardant (United States)), Jennifer C. Keenan(Massachusetts General Hospital), Jochen K. Lennerz(Massachusetts General Hospital), Lauren Oshry(Boston Medical Center), Sofia Menshikova(Addgene), Rachel O. Abelman(Massachusetts General Hospital), Anna Butusova(Addgene), Beverly Moy(Massachusetts General Hospital)
Cited by 11
Related Papers
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling
|Genes & Development|2008|696